

**Solent Multiple Sclerosis
Therapies Limited**

Financial Accounts for the Period Ended

31 March 2026

Company Registration Number: 2215154

THURSDAY



AF2JM000

A01

21/05/2026

#125

COMPANIES HOUSE

Solent Multiple Sclerosis Therapies Limited
Report and Accounts for the Period Ended 31 March 2026

CONTENTS	PAGES
Report of the Directors	1
Independent Examiner's Report	2
Statement of Financial Activities	3
Income and Expenditure Account	4
Balance Sheet	5-6
Notes to the Accounts	7-10

The following pages do not form part of the statutory accounts.

Summary Income and Expenditure Account	11
Income Detail	12
Physio/Osteo/Reflex/Shiatsu analysis	13
Bank Balances	14
Fixed Assets	15
Detailed Income and Expenditure Account	16

Solent Multiple Sclerosis Therapies Limited
Accounts for the Period Ended 31 March 2026

Trustees R Hayter - Acting Chairman

P Lee
A Alexander
A Sandford
R Moorhen
K Ebbens
K Silman
L Rickman
C Alexander

Registered Office Bradbury House
56 Hewett Road
North End
Portsmouth
Hampshire
PO2 0QP

Bankers Lloyds TSB plc
16A High Street
Cosham
Portsmouth
Hampshire
PO6 3BY

Company Number 2215154

Accountants Hunter Simmons Ltd
3a London Road
Purbrook
Waterlooville
Hampshire
PO7 5LQ

Solent Multiple Sclerosis Therapies Limited

Report of the Directors for the Period Ended 31 March 2026

Report of the Directors

The directors herewith present the accounts for the period ended 31 March 2026.

Activities of the Company

The company's principal activity is to aid the condition of those suffering from multiple sclerosis by providing guidance, practical support and therapy to those such persons.

Directors

The directors of the company throughout the year were as follows:

A Sandford	R Hayter	S Emery (Resigned 02.06.25)
A Alexander	K Silman	P Lee
R Moorhen	L Clarke (Resigned 18.07.25)	C Alexander
L Rickman	K Ebbens (Resigned 11.01.26)	

The directors do not hold any shares in the company.

Charitable Status

The company is a registered charity with the Charity Commissioners in England and Wales.

Company Number and Charity Number

The company registered number is 2215154 and the Registered Charity number is 299545.

Governing Document

The governing document is the Memorandum and Articles of Association.

Trustees

The directors have produced a Directors' Report as required by Company Law instead of a Trustees' Report.


Registered Office

The registered office of the charity is Bradbury House, 56 Hewett Road, North End, Portsmouth, Hampshire PO2 0QP.

Exemptions

Advantage has been taken in the preparation of the Directors' Report of the special exemptions applicable to small companies conferred by Part 15 of the Companies Act 2006.

By Order of the Board

..........R Hayter - Chairman

Dated.....15 MAY 2026.....

Independent Examiner's Report to the Trustees of Solent Multiple Sclerosis Therapies Limited

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2026.

Responsibilities and basis of report

As the trustees of the Charity (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that that accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by Charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)]

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Sean Hunter, FFP FIPA
Institute of Financial Accountants
Membership Number: 232174

Hunter Simmons Ltd
3a London Road
Purbrook
Waterlooville
Hampshire
PO7 5LQ

Date 15 MAY 2026

Solent Multiple Sclerosis Therapies Limited
Statement of Financial Activities
For the Period Ended 31 March 2026

	Notes	Mar-26 £	Mar-25 £
General Fund			
Incoming Resources:			
Donations:			
Donations and Gifts		132,506	155,102
Investment Income		1,087	1,209
Income from trading activities:			
Related to objects of the charity		0	0
Total incoming resources		<u>133,593</u>	<u>156,311</u>
Resources Expended:			
Direct Charitable Expenditure		54,507	56,545
Fund Raising and Publicity		7,924	11,390
Management and Administration	3	98,369	99,763
Total resources expended	4	<u>160,800</u>	<u>167,698</u>
Net incoming resources	5	(27,207)	(11,387)
Balances at 31 March 2025		331,898	343,285
Balances at 31 March 2026		<u>304,691</u>	<u>331,898</u>

Solent Multiple Sclerosis Therapies Limited
Income and Expenditure Account
For the Period Ended 31 March 2026

	Mar-26 £	Mar-25 £
Total Income from continuing operations	133,593	156,311
Total expenditure from continuing operations	160,800	167,698
Net income/(expenditure) for the year	<u>(27,207)</u>	<u>(11,387)</u>

There are no recognised gains or losses in 2026 or 2025 other than the net income for the years.

Solent Multiple Sclerosis Therapies Limited
Balance Sheet
As at 31 March 2026

	Notes	Mar-26		Mar-25	
		£	£	£	£
Fixed Assets					
Tangible Assets	8		202,931		209,416
Current Assets					
Stocks	9		-		-
Prepayments			3,945		3,261
Cash at Bank and in Hand			120,738		146,591
			<u>124,683</u>		<u>149,852</u>
Creditors: Amounts due within one year					
Other creditors	10		<u>3,835</u>		<u>8,282</u>
Net Current Assets			120,848		141,570
Total Net Assets			<u>323,779</u>		<u>350,986</u>
Fund Balances					
Income and Expenditure Account			304,691		331,898
Reserved Capital			3,200		3,200
Operating Reserve Account			15,888		15,888
Total Fund Balances			<u>323,779</u>		<u>350,986</u>

The Balance Sheet continues on the following page
The notes on pages 7 to 10 form part of these accounts

Solent Multiple Sclerosis Therapies Limited
Balance Sheet (continued)
As at 31 March 2026

Directors' Statement

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies, for the period ended 31 March 2026.


The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies and with the Financial Reporting Standard for Smaller Entities (effective April 2008).

These accounts were approved on... 15 MAY 2026


..... R Hayter - Director


..... L Rickman - Director

The notes on pages 7 to 10 form part of these accounts

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2026

1 ACCOUNTING POLICIES

Basis of Accounting

These accounts have been prepared on the basis of the historical cost convention in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008) and with applicable Accounting Standards, the Accounting and Reporting by Charities - Statement of Recommended Practice (SORP 2005) and the Charities Act 1993.

Incoming Resources

Incoming resources are reported gross.

Legacies and Donations

Legacies and donations are accounted for when the resources are receivable or when the charity's entitlement is legally enforceable. Legacies received in the form of property and investments are credited at the lower of probate and market value. Other gifts in kind are included in the accounts at market value. Assets for distribution are recognised only when distributed; assets given for use by the charity are recognised when receivable; stocks of unsold donated goods are not valued for balance sheet purposes.

Grants Receivable

Grants are recognised when receivable.

Direct Charitable Expenditure, Fund Raising, Management and Administration

Direct charitable expenditure comprises all expenditure directly relating to the objects of the charity. When necessary, costs are allocated between direct charitable expenditure fund-raising and management and administration on the basis of apportionment of the relevant expenditure.

Life Subscriptions

There are no life subscriptions

Commitments

Commitments made by the directors that are legally binding have been accrued. Those that are not legally binding have not been charged in the accounts, but disclosed in note 11.

Tangible Fixed Assets and Depreciation

Tangible fixed assets are stated at cost.

Depreciation is provided over the expected useful lives of each category of tangible fixed asset as follows:

Furniture and Office Equipment	25% on net book value
Plant and Equipment	25% on net book value
Buildings	Depreciated to reflect a valuation of £35000
Improvements to Freehold Property	2% on cost
The Compression Chamber and previous Improvements to Freehold Property are fully depreciated.	
Freehold Land has not been depreciated.	

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2026

1 ACCOUNTING POLICIES (continued)

Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for any obsolete or slow-moving items. Cost includes direct materials, labour and overheads incurred in providing each service. Net realisable value is based on estimated selling price less selling costs.

Cash Flow Statement

The company has taken advantage of the exemption in the Financial Reporting Standard 1 from the requirement to disclose a Statement of Cash Flows on the grounds that it is a small company.

2 INVESTMENT INCOME

	Mar-26	Mar-25
	£	£
Bank Interest Receivable	<u>1,087</u>	<u>1,209</u>

3 MANAGEMENT AND ADMINISTRATION

	Mar-26	Mar-25
	£	£
Central Management and Administration	<u>98,369</u>	<u>99,763</u>

4 ANALYSIS OF TOTAL RESOURCES EXPENDED

	Mar-26	Mar-25
	£	£
Salaries	89,109	86,092
Utilities	3,041	3,790
Supplies	62,165	68,117
Depreciation/Loss on disposal	6,485	9,699
	<u>160,800</u>	<u>167,698</u>

5 NET INCOMING RESOURCES

	Mar-26	Mar-25
	£	£
This is stated after charging:		
Depreciation/Loss on disposal	<u>6,485</u>	<u>9,699</u>

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2026

6 INTEREST PAYABLE LESS RECEIVABLE

	Mar-26 £	Mar-25 £
Bank Interest Receivable	<u>1,087</u>	<u>1,209</u>

7 TAXATION

No corporation tax is payable as the company is a registered charity.

8 TANGIBLE FIXED ASSETS

	Imp's to Freehold Property	Freehold Property	Com- pression Chamber	Plant and Equipment	Furniture and Office Equipment	Total
Cost						
Brought Forward	254,222	39,884	22,244	62,076	6,576	385,002
Additions						-
Disposals				-		-
Carried Forward	<u>254,222</u>	<u>39,884</u>	<u>22,244</u>	<u>62,076</u>	<u>6,576</u>	<u>385,002</u>
Depreciation						
Brought Forward	85,401	4,884	22,244	59,102	3,955	175,586
Charge for the year	5,084			744	657	6,485
Eliminated on disp's						-
Carried Forward	<u>90,485</u>	<u>4,884</u>	<u>22,244</u>	<u>59,846</u>	<u>4,612</u>	<u>182,071</u>
Net Book Value						
At 31.03.26	<u>163,737</u>	<u>35,000</u>	<u>-</u>	<u>2,230</u>	<u>1,964</u>	<u>202,931</u>
At 31.03.25	<u>168,821</u>	<u>35,000</u>	<u>-</u>	<u>2,974</u>	<u>2,621</u>	<u>209,416</u>

The Improvements to Freehold Property represent the costs incurred for the major refurbishment of the Therapy Centre at Hewett Road, North End, Portsmouth.

The works were completed in 2008.

9 STOCK

	Mar-26 £	Mar-25 £
Goods for resale	<u>-</u>	<u>-</u>

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2026

10 CREDITORS: AMOUNTS DUE WITHIN ONE YEAR

	Mar-26	Mar-25
	£	£
Taxation and social security	1,354	1,779
Accruals	2,309	3,667
Other creditors	172	2,836
	<u>3,835</u>	<u>8,282</u>

11 LIMITED LIABILITY

Every member of the company undertakes to contribute to the assets of the company, in the event of the company being wound up, an amount not exceeding £1.

Solent Multiple Sclerosis Therapies Limited
Summary Income and Expenditure Account
For the Period Ended 31 March 2026

	Mar-26	Mar-25
	£	£
Income	133,593	156,311
	<u>133,593</u>	<u>156,311</u>
Expenditure		
Oxygen	11,445	9,519
Splints	0	0
Salaries	89,109	86,092
Building and Equipment Repairs and Renewals	9,324	12,860
Utilities	3,041	3,790
General Office and Running Costs	12,900	12,367
Insurance Premiums	6,032	4,512
Diet Supplements, Vitamins and Goods for Resale	606	537
Provision of Physio and Therapists	14,056	20,410
Fund Raising Expenses	5,877	6,612
Professional Fees	1,925	1,300
HMRC Penalty	0	0
Depreciation	6,485	9,699
	<u>160,800</u>	<u>167,698</u>
Net Surplus/(Deficit) for the Year	<u>(27,207)</u>	<u>(11,387)</u>

Solent Multiple Sclerosis Therapies Limited
Income Detail
For the Period Ended 31 March 2026

	Mar-26	Mar-25
	£	£
Bank interest	1,087	1,209
Book sales (Ziffit)	306	364
Bonus ball	590	1,256
Collections	90	354
Community events	7,133	21,025
Corporate grants	483	7,474
Direct debit donations	1,720	1,626
Ebay/Vinted/Charity Shop	21,256	19,442
EPO/APS/Masks	1,062	969
Gift aid	2,533	3,162
HDOT donation	60,576	63,430
Individual donations	3,883	4,695
Inductions	2,200	3,358
Masons donations	-	-
Membership	8,302	7,454
National lottery grant	-	-
Office bottles	3,262	2,960
Physio donation	7,804	7,952
Portsmouth lottery	277	260
Reflex donations	7,060	7,767
Solar panel payment	1,670	1,484
Sponsored events	2,299	70
Trust donations	-	-
	<u>133,593</u>	<u>156,311</u>

Solent Multiple Sclerosis Therapies Limited
Therapy Analysis
For the Period Ended 31 March 2026

	Donations	Costs	Surplus/ (Deficit)
	£	£	£
Physio	7,804	6,292	1,512
Osteo	0	0	0
Reflex	7,060	4,495	2,565
	<u>14,864</u>	<u>10,787</u>	<u>4,077</u>

Solent Multiple Sclerosis Therapies Limited
Bank Analysis
For the Period Ended 31 March 2026

	Mar-26	Mar-25
Lloyds TSB		
Current account	120,087	58,015
CAF Bank accounts		
CAFCash account	-	-
Scottish Widows Bank	-	1,069
Air Receiver & Deluge Tank Fund	-	-
HDOT chamber emergency replacement reserve	-	87,215
Paypal	57	88
Total Bank Balances	<u>120,144</u>	<u>146,387</u>
Cash in hand	594	204
Total Bank and Cash	<u>120,738</u>	<u>146,591</u>
Balance per accounts	120,738	146,591

Solent Multiple Sclerosis Therapies Limited
Fixed Assets
For the Period Ended 31 March 2026

	Imp's to Freehold Property	Freehold Property	Com- pression Chamber	Plant and Equipment	Furniture and Office Equipment	Total
Cost						
Brought Forward	254,222	39,884	22,244	62,076	6,576	385,002
Additions	-	-	-	-	-	-
Disposals	-	-	-	-	-	-
Carried Forward	<u>254,222</u>	<u>39,884</u>	<u>22,244</u>	<u>62,076</u>	<u>6,576</u>	<u>385,002</u>
Depreciation						
Brought Forward	85,401	4,884	22,244	59,102	3,955	175,586
Charge for the year	5,084	-	-	744	657	6,485
Eliminated on disp's	-	-	-	-	-	-
Carried Forward	<u>90,485</u>	<u>4,884</u>	<u>22,244</u>	<u>59,846</u>	<u>4,612</u>	<u>182,071</u>
Net Book Value						
At 31.03.26	<u>163,737</u>	<u>35,000</u>	<u>-</u>	<u>2,230</u>	<u>1,964</u>	<u>202,931</u>
At 31.03.25	<u>168,821</u>	<u>35,000</u>	<u>-</u>	<u>2,974</u>	<u>2,621</u>	<u>209,416</u>

Solent Multiple Sclerosis Therapies Limited
Detailed Income and Expenditure Account
For the Period Ended 31 March 2026

		Mar-26 £	Mar-25 £
Income		133,593	156,311
		<u>133,593</u>	<u>156,311</u>
Direct Costs			
Fund Raising Costs		5,877	6,612
Provision of Physio and Therapists	14,056		
less contribution	<u>0</u>	14,056	20,410
Oxygen	11,445		
less contribution	<u>0</u>	11,445	9,519
Splints		0	0
EPO		606	537
Payroll Costs		<u>89,109</u>	<u>86,092</u>
		<u>121,093</u>	<u>123,170</u>
Gross Surplus		<u>12,500</u>	<u>33,141</u>
Overheads			
Building and Equipment Repairs and Renewals		9,324	12,860
Utilities		3,041	3,790
General Office and Running Costs		12,900	12,367
Professional Fees		1,925	1,300
HMRC Penalty		0	0
Depreciation/Loss on disposal		6,485	9,699
Insurance		<u>6,032</u>	<u>4,512</u>
		<u>39,707</u>	<u>44,528</u>
Net Surplus/(Deficit) for the year		<u>(27,207)</u>	<u>(11,387)</u>
Building and Equipment Repairs and Renewals			
Repairs and Maintenance			
Building		6,039	8,745
Chamber		<u>3,285</u>	<u>4,115</u>
		<u>9,324</u>	<u>12,860</u>
General Office and Running Costs			
Staff Training		0	1,022
Miscellaneous		500	1,103
Telephone		804	819
Postage and Stationery		620	708
Computer Costs		5,183	4,223
Subscriptions		400	480
Bank charges		254	323
Cleaning and Hygiene		<u>5,139</u>	<u>3,689</u>
		<u>12,900</u>	<u>12,367</u>